SecBot SecBot
8-K ·Filed Nov 4, 2026

XNCR

Xencor Inc
NEUTRAL
Impact 5/10
Horizonmonths Processed12d 10h ago SEC0001326732-26-000062
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The large EPS and revenue beat is driven by non-recurring milestones and royalty payments, not core operating leverage. Watch for XmAb819 FDA engagement in 1H27 and the XENITH-UC interim analysis around year-end 2026 for pipeline catalysts.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

XNCR drug pipeline →

XmAb819

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
Unknown — pivotal study start is planned for 2027, meaning FDA approval would likely be several years away if Phase 2/3 data are positive.
Next catalyst
None dated

What to watchWatch the ESMO 2026 oral presentation (likely October 2026) for updated Phase 1 dose-expansion data, specifically whether the 25% ORR holds or improves in a larger cohort and whether the safety profile (primarily Grade 1-2 CRS, rash, GI events) remains manageable. The pivotal study start in 2027 is the next major milestone after that. XNCR's ~$26 stock price already reflects a mean analyst target of $29, limiting near-term upside absent a clear data beat.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$34.05
T+0 close · Nov 4, 2026 · via day close
Latest settled
+11.98%
T+5 · $38.13 · next T+20 in 17d
Vs SPY
+8.69%
α at T+5
Latest observation
+5.46%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $34.05entry
  2. T+1 · 11d ago +4.99%α +4.68% · $35.75
  3. T+5 · 5d ago +11.98%α +8.69% · $38.13
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xencor reported Q3 2026 revenue of $116.5M (vs consensus $63.0M) and GAAP diluted EPS of $0.50 (vs consensus $-0.34), driven by milestone and royalty revenue from partners. The beat was largely non-operational, reflecting a $25M Astellas milestone and $52.5M Alexion settlement payment, while R&D spending rose to $84.3M. Pipeline highlights include XmAb819 45.5% confirmed ORR at 400 mcg/kg in ccRCC and plans to initiate a Phase 3 study by end of 2027.

Key Financial Metrics

EPS
$0.50
est −$0.34 · +247.1%
Revenue
$116.5M
est $63.0M · +84.9% · +454.8% YoY
Rating
beat

Key Facts

  • Q3 2026 revenue $116.5M vs $21.0M YoY, primarily from royalties and milestones
  • GAAP diluted EPS $0.50 vs net loss of $(0.08) in Q3 2025
  • Consensus was EPS $-0.34 and revenue $63.0M; EPS beat by $0.84, revenue beat by $53.5M
  • R&D expenses $84.3M, up from $54.4M YoY, driven by higher program costs
  • Cash and marketable securities $555.7M at Sep 30, 2026; guidance for $480M-$500M year-end 2026
  • XmAb819 400 mcg/kg IV dose showed 45.5% confirmed ORR in ccRCC; Phase 3 planned by end 2027
  • Astellas milestone of $25.0M triggered by ASP2138 Phase 3 first patient dosed
  • Zenas BLA for obexelimab accepted by FDA; $2.5M milestone from Japan MAA submission

Financial Impact

Revenue $116.5M vs consensus $63.0M; GAAP EPS $0.50 vs consensus $-0.34; cash burn from operations with $555.7M cash position

revenueepscashr&d spending

Risk Factors

  • Revenue beat driven by one-time milestones and settlement payments, not sustainable
  • R&D spending increased 55% YoY to $84.3M, pressuring operating cash flow
  • Cash burn from operations: cash declined from $610.8M (Dec 2025) to $555.7M (Sep 2026)
  • XmAb819 Phase 3 study not yet initiated; regulatory feedback on accelerated pathway pending

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001326732-26-000062
Document: xncr-20261104.htm0001326732-26-000062
Document: 0001326732-26-000062-index-headers.html0001326732-26-000062
Document: 0001326732-26-000062-index.html0001326732-26-000062
Document: 0001326732-26-000062.txt0001326732-26-000062
8-K Data (Synthetic)0001326732-26-000062

Track record

20 reports on XNCR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
  3. Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
  6. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
  7. Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
  8. Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
  9. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026